Francisco Vizcarrondo
Hematology & Oncology · Birmingham, ALNPI 1487760328
Payments from drug & device makers
$2,181,554in general payments, 2019–2025
Across 502 payments — averaging $4345.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$544K
- Merck$393K
- Seagen Inc.$357K
- Incyte Corporation$268K
- Boehringer Ingelheim$193K
- AstraZeneca$107K
- plus $319K from 11 others
General payments by program year
19
20
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 143 | $543,923 |
| Merck | 59 | $393,322 |
| Seagen Inc. | 60 | $356,647 |
| Incyte Corporation | 149 | $267,511 |
| Boehringer Ingelheim | 9 | $193,202 |
| AstraZeneca | 5 | $107,488 |
| Amgen | 5 | $72,259 |
| GSK | 14 | $64,194 |
| E.r. Squibb & Sons, L.L.C. | 1 | $51,810 |
| Regeneron | 12 | $50,849 |
| Eli Lilly | 4 | $36,541 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $19,643 |
| EMD Serono, Inc. | 12 | $16,593 |
| Genentech USA, Inc. | 8 | $3,789 |
| Pfizer | 2 | $2,180 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 3 | $1,592 |
| BD | 1 | $11 |
How this compares
$2,181,554 in reported general payments places this provider in the 90th percentile of 177 hematology & oncology providers in Alabama.
Other hematology & oncology in Birmingham
- Luciano CostaBirmingham$32.8M
- Amitkumar MehtaBirmingham$18.6M
- Erica Stringer-ReasorBirmingham$18.1M
- Susan BalBirmingham$11.3M
- Pankit VachhaniBirmingham$7.9M
- Mehmet AkceBirmingham$5.4M
- Mayur NarkhedeBirmingham$4.9M
- Christos VaklavasBirmingham$4.9M
- Lisle NabellBirmingham$3.3M
- Omer JamyBirmingham$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.